Talk Bio

The U.S. Food and Drug Administration (FDA) has recently released 14 previously unpublished drug rejection letters as part of its expanded transparency policy, marking the first such release after a 3‑month pause in the publication of complete response letters (CRLs). These letters had been issued to sponsors between 2020 and 2024 and were held back while the Department of Health and Human Services (HHS) reviewed the legal and procedural framework for public disclosure of rejection letters for unapproved drugs. The pause followed a citizen’s petition from a pharmaceutical company that raised concerns about patient privacy and commercial confidentiality, prompting HHS to develop a formal rule for disclosure. The 14 new letters, making up the latest tranche of CRLs added to the FDA’s public database, disclose common reasons for non‑approval, such as safety and efficacy concerns, manufacturing deficiencies, and bioequivalence issues, after redacting trade secrets and confidential informat...